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Introduction
Percutaneous mitral valve repair with the Mitraclip system
(Abbott, Abbott Park, Illinois, United States) has recently
emerged as a safe and effective procedure to treat patients
withdegenerativemitral regurgitation (MR)withhighsurgical
risk and a technically favorable anatomy. TheMitraclip is being
extensively used also to treat functional MR in patients with
persisting heart failure symptoms despite optimal medical
treatment and, when indicated, cardiac resynchronization
therapy (CRT).1 The guiding catheter is advanced from the
femoral vein to the left atrium through a transseptal approach.
Then, guided by transesophageal echocardiography (TEE), one
or more clips are placed on the mitral valve leaflets through a
steerable delivery system, to permanently approximate the
leaflets and create a double valve orifice.
Interventional cardiology procedures require full antic-
oagulation to prevent thrombus formation on catheters and
devices with potential development of embolic complica-





Abstract Interventional cardiology procedures require full anticoagulation to prevent thrombus
formation on catheters and devices with potential development of embolic complications.
Bivalirudin, a short half-life direct thrombin inhibitor, has been largely used during
percutaneous coronary interventions and represents the preferred alternative to heparin
in patients with heparin-induced thrombocytopenia (HIT). However, few data are available
about intraprocedural use of bivalirudin during transcatheter structural heart disease
interventions. Activated clotting time (ACT) monitoring during bivalirudin infusion pre-
sents some limitations and it is not mandatory. We report a case of bivalirudin use in a
patient with type-2 HIT during percutaneous mitral valve repair with the Mitraclip system
(Abbott, Abbott Park, Illinois, United States). Despite use of standard bivalirudin dose (0.75
mg/kg bolus and 1.4 mg/kg/min infusion—reduced infusion rate was motivated by a
glomerular filtration rate of 37 mL/min), the patient developed a large thrombus on
the second clip during its orientation toward the mitral orifice. ACTwas measured at that
time and was suboptimal (240 seconds). The case was successfully managed with clip and
thrombus retrieval, adjunctive 0.3mg/kg bivalirudin bolus and increased infusion rate, and
clip repositioning with ACT monitoring. This report makes the case for mandatory ACT
checking and drug titration during high-risk catheter–based structural heart disease
interventions, even when thromboprophylaxis is performed with bivalirudin. Additional
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of bulky devices into the left atrium, a chamber characterized
by low blood flowvelocities, especially in patients with atrial
fibrillation and a dilated atrium. Hence, thrombotic risk is
high and intraprocedural antithrombotic management must
be very accurate. In general, an initial bolus of heparin is
given after transseptal puncture and activated clotting time
(ACT) is monitored to administer additional doses and main-
tain an ACT value greater than 250 seconds.
Heparin-induced thrombocytopenia (HIT) is a potentially
catastrophic immune-mediated complication of heparin
caused by antibodies to complexes of platelet factor-4
(PF4) and heparin.2 HIT predisposes to thrombosis because
platelets release microparticles that activate thrombin. In
patients undergoing percutaneous coronary intervention
(PCI) with a diagnosis of HIT, intraprocedural administration
of bivalirudin is recommended.
We report the challenging management of a patient with
HIT who underwent Mitraclip procedure with bivalirudin
infusion.
Case Presentation
An 81-year-old woman with dilated cardiomyopathy was
referred to our institution for urgent Mitraclip procedure
because of severe MR and heart failure refractory to full
medical treatment, includinghigh-dose intravenous (IV)diure-
tics. Echocardiography showed severe left ventricular dilata-
tion, with 20% ejection fraction, severe left and right atrial
enlargement, and severe functionalmitral and tricuspid regur-
gitation (►Fig. 1). Comorbidity included type 2 HIT, chronic
hepatitis C virus infection, chronic anemia, chronic kidney
disease (CKD) with glomerular filtration rate 37 mL/min,
previous mammary cancer followed by radiotherapy (40 years
before), andpreviousoperatedcolonadenocarcinoma(10years
before). Baseline activated partial thromboplastin time (aPTT),
international normalized ratio (INR), and fibrinogen were
within normal limits. The patient had received CRT-D 4 years
earlier. Ongoing therapy: furosemide 500 mg/die IV, carvedilol
6.25 mg bid, potassium canrenoate 100 mg, iron supplement,
pantoprazole, levothyroxine, and levosimendan.
The Mitraclip procedure was conducted with standard
technique. Saline solutionwithout heparinwas used for cathe-
ters’ flushing. We administered bivalirudin bolus (0.75 mg/kg
IV) immediately after transseptal puncture and at the same
time a PCI-dose infusion of 1.40 mg/kg per hour was started
(recommended dose reduction for CKD).
After release of the first clip, during positioning of
a second clip to improve procedural result, a moving image
suggestive for thrombus became evident on top of the clip
(►Fig. 1 and ►Video 1). ACT measured 240 seconds. An
additional bivalirudin bolus of 0.3 mg/kg was administered
and the infusion rate increased to 1.75mg/kg/hour. Themass
did not reduce and actually tended to increase. Hence, the
clip was carefully removed to avoid embolization. Once
outside the catheter, a large thrombus attached to the clip
was evident (►Fig. 1, panel D). Then, a line for additional
bivalirudin continuous infusion (and flushing) was placed
directly on the guiding catheter, at a rate of 0.2 mg/kg/hour.
ACT then measured 455 seconds. The procedure was suc-
cessfully completed with reduction of MR grade from 4þ to
1þ . Bivalirudin infusionwas stopped and the guiding cathe-
ter removed without complications. No clinical signs of
Fig. 1 Intraprocedural echocardiography and clip thrombosis. (A) Intraprocedural transesophageal echocardiography (TEE) color Doppler at the left
ventricular outflow tract view showing severe mitral regurgitation (MR). (B) TEE at the intercommissural view showing the extension of severe MR to the
entiremitral valve orifice. (C) Thrombus adherent to the clip during themaneuvers to orient the second clip toward themitral orifice. LA, left atrium; LV, left
ventricle. (D) Picture of the clip and the thrombus once retrieved from the patient. (E) Double orifice of the mitral valve at 3D echocardiography after
implantation of the two clips. (F) Final procedural result with residual trivial mitral regurgitation, X-plane view.
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embolization appeared, although we cannot rule out small
silent systemic embolizations. The patient was discharged
home after 1 week. Antithrombotic regimen was lifelong
aspirin and clopidogrel for 6 months.
Video 1
Intraprocedural transesophageal echocardiography
showing the sessile thrombus attached to the clip.




Bivalirudin is a direct thrombin inhibitor with short half-life
which has been widely used for anticoagulation in the setting
of PCI, and represents the first-line intraprocedural anticoa-
gulant for patientswithHIT. It is administeredwith a 0.75-mg/
kg bolus, followed by infusion of 1.75 mg/kg/hour in patients
with GFR greater than 60mL/min, reduced to 1.40mg/kg/min
in patients with GFR 30 to 59mL/min. An infusion at 0.25mg/
kg/hour can be prolonged 4 to 12 hours if clinically indicated.
ACT can be used to monitor effective bivalirudin administra-
tion, but it is not routinely recommended. Safety and efficacy
of bivalirudin in structural heart disease procedures havebeen
poorly investigated. The Effect of Bivalirudin on Aortic Valve
Intervention Outcomes-3 (BRAVO-3) randomized trial
demonstrated noninferiority of bivalirudin compared with
heparin in rates of major bleeding or net adverse cardiovas-
cular events during transcatheter aortic valve implantation.3
Yet, flow in the left ventricular outflow tract is torrential and
thrombotic risk is supposedly lower than that in the left
atrium. There are a few reports about successful bivalirudin
use during ablation procedures in patients with HIT.4,5 To the
best of our knowledge, this is thefirst report of bivalirudin use
in a patient undergoing a Mitraclip procedure.
Despite the use of recommended bivalirudin dose, our
patient developed a large thrombus on the clip during the
procedure. ACT was measured only at that time and was
actually lower than expected. The procedure was success-
fully completed giving an additional 0.3 mg/kg bolus, as per
indications for use, and arbitrary continuous catheter flush-
ing with a low bivalirudin dose.
Limitations of ACT monitoring of bivalirudin therapy have
been previously demonstrated,6 and there is no guidance
regardingwhat valueofACTwouldwarrant anadditional bolus.
Accordingly, routine monitoring of ACT during PCI is not
mandatory and is not usually performed. However, the
instructions for use suggest to check ACT 5 minutes after
the bolus and to administer additional 0.3 mg/kg bolus dose
“if needed.” In our case, this was necessary to achieve
effective thromboprophylaxis. We also increased infusion
rate and continuously flushed the guiding catheter with low-
dose bivalirudin.
Differently from heparin, bivalirudin binds directly to
thrombin without the need of a cofactor and therefore
exhibits predictable and dose-dependent anticoagulation.
While bivalirudin activity is independent of antithrombin
deficiency, increased heparin clearance, and increased
heparin binding proteins, which are among the causes of
heparin resistance, other resistance mechanisms such as
heparin have been hypothesized, including elevated factor
VIII and fibrinogen.7 Furthermore, because bivalirudin inhi-
bits both free and clot-bound thrombin, in the presence of
large clot burden higher dosingmight be required because of
the larger number of binding sites.7 In our patient, fibrinogen
was normal and there was no clinical evidence of vascular
thrombosis. Additional coagulation tests were not per-
formed; so, we cannot rule out abnormality of factor VIII
level or the presence of unrecognized vascular thrombosis.
Interestingly, bivalirudin resistance (defined as ACT < 300
seconds) was reported in 2.4% of patients undergoing PCI in a
single-center study.8 While bleeding complications were not
more common in bivalirudin hyperresponders (ACT > 800
seconds), thrombotic complications were numerically higher
in bivalirudin hyporesponders.8 Overall, the therapeutic win-
dow seemswide enough to allow additional bivalirudin doses
in suspectedbivalirudin hyporesponders, based onACTvalues.
Remarkably, however, monitoring of direct thrombin inhibi-
tor’s efficacy would require more sensitive markers, such as
the chromogenic anti-Xa level for heparin, dilute thrombin
time, Ecarin thrombin time, and specific chromogenic sub-
strate-based assays, although clinical applicability is limited
because of the lack of widely available commercial products.7
Conclusion
This case suggests that bivalirudin may be used in place of
heparin in patients with HIT undergoing Mitraclip proce-
dure. However, bivalirudin might be subject to resistance
mechanisms similar to those previously described in
patients receiving heparin, and careful ACT monitoring
should bemandatory to verify achievement and permanence
in the therapeutic range. When possible, additional coagula-
tion tests should be used. Flushing of guiding catheters and
devices with low-dose bivalirudin may represent a useful
adjunctive measure. More data are needed to clarify if
different ways of monitoring bivalirudin therapy are
required for transcatheter structural heart disease interven-
tions. Importantly, this is a single clinical case and our
observations should be interpreted cautiously.
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